Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Source: SeekingAlpha
2025-07-18 12:02:14 ET
Investment Overview
When I last covered Iovance Biotherapeutics, Inc. ( IOVA ) in a note for Seeking Alpha back in early April, I gave the San Carlos, California based biotech's stock a Sell rating, with shares priced at $3.25. That has proven to be the correct call so far, as stock currently trades at $2.34, down ~28%....
Read the full article on Seeking Alpha
For further details see:
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-10.42% G/L:
$4.6493 Last:
4,448,331 Volume:
$5.06 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
